Kinase activity is required for the toxic effects of mutant LRRK2/dardarin

被引:611
作者
Greggio, Elisa
Jain, Shushant
Kingsbury, Ann
Bandopadhyay, Rina
Lewis, Patrick
Kaganovich, Alice
van der Brug, Marcel P.
Beilina, Alexandra
Blackinton, Jeff
Thomas, Kelly Jean
Ahmad, Rill
Miller, David W.
Kesavapany, Sashi
Singleton, Andrew
Lees, Andrew
Harvey, Robert J.
Harvey, Kirsten
Cookson, Mark R.
机构
[1] NIA, Cell Biol & Gene Express Unit, Lab Neurogenet, Bethesda, MD 20892 USA
[2] NIA, Mol Genet Unit, Neurogenet Lab, Bethesda, MD 20892 USA
[3] Inst Neurol, Reta Lila Weston Inst Neurol, London WC1N 1PJ, England
[4] NINDS, Neurochem Lab, Bethesda, MD 20892 USA
[5] Univ London Sch Pharm, Dept Pharmacol, London WC1N 1AX, England
关键词
LRRK2; kinase; Parkinson's disease; alpha-synuclein; substantia nigra;
D O I
10.1016/j.nbd.2006.04.001
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Mutations in the LRRK2 gene, coding for dardarin, cause dominantly inherited Parkinson's disease (PD). Dardarin is a large protein, and mutations are found throughout the gene including the kinase domain. However, it is not clear if kinase activity is important for the damaging effects of pathogenic mutations. In this study, we noted two cellular phenotypes associated with mutant dardarin. First, pathogenic mutations increase the tendency of dardarin to form inclusion bodies. Secondly, neurons and neuronal cell lines undergo cell death after expression of mutant protein. Manipulating activity by replacing the kinase domain with a 'kinase-dead' version blocks inclusion body formation and strongly delays cell death. This predicts that kinase inhibitors will be useful therapeutic agents in patients with LRRK2 mutations and, perhaps, in sporadic PD. We also show that dardarin protein is expressed within human midbrain neurons and that C-terminal epitopes are also found in some Lewy bodies. Published by Elsevier Inc.
引用
收藏
页码:329 / 341
页数:13
相关论文
共 28 条
  • [1] LRRK2 mutations and Parkinsonism
    Albrecht, M
    [J]. LANCET, 2005, 365 (9466) : 1230 - 1230
  • [2] Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
    Arrasate, M
    Mitra, S
    Schweitzer, ES
    Segal, MR
    Finkbeiner, S
    [J]. NATURE, 2004, 431 (7010) : 805 - 810
  • [3] Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability
    Beilina, A
    Van Der Brug, M
    Ahmad, R
    Kesavapanyt, S
    Miller, DW
    Petsko, GA
    Cookson, MR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (16) : 5703 - 5708
  • [4] Roc, a Ras/GTPase domain in complex proteins
    Bosgraaf, L
    Van Haastert, PJM
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2003, 1643 (1-3): : 5 - 10
  • [5] Presenilin function and γ-secretase activity
    Brunkan, AL
    Goate, AM
    [J]. JOURNAL OF NEUROCHEMISTRY, 2005, 93 (04) : 769 - 792
  • [6] The biochemistry of Parkinson's disease
    Cookson, MR
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 2005, 74 : 29 - 52
  • [7] How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease
    Cookson, MR
    Xiromerisiou, G
    Singleton, A
    [J]. CURRENT OPINION IN NEUROLOGY, 2005, 18 (06) : 706 - 711
  • [8] Intracellular clusterin causes juxtanuclear aggregate formation and mitochondrial alteration
    Debure, L
    Vayssière, JL
    Rincheval, V
    Loison, F
    Le Dréan, Y
    Michel, D
    [J]. JOURNAL OF CELL SCIENCE, 2003, 116 (15) : 3109 - 3121
  • [9] An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family
    Funayama, M
    Hasegawa, K
    Ohta, E
    Kawashima, N
    Komiyama, M
    Kowa, H
    Tsuji, S
    Obata, F
    [J]. ANNALS OF NEUROLOGY, 2005, 57 (06) : 918 - 921
  • [10] A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1
    Funayama, M
    Hasegawa, K
    Kowa, H
    Saito, M
    Tsuji, S
    Obata, F
    [J]. ANNALS OF NEUROLOGY, 2002, 51 (03) : 296 - 301